ZG005 plus gecacitinib (with or without bevacizumab) for advanced cervical cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, open-label Phase 1/2 trial gives adults with advanced cervical cancer an experimental antibody, ZG005, combined with the JAK inhibitor gecacitinib, and some participants may also receive bevacizumab. The Phase 1 portion focuses on safety and tolerability to identify appropriate dosing, and the Phase 2 expansion looks for preliminary signs of anti-tumor activity. Key outcomes include adverse events, dose-limiting toxicities, and measures of tumor response and progression. Eligible participants must have histologically or cytologically confirmed advanced cervical cancer and an ECOG performance status of 0 or 1.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Fully understand the study and voluntarily sign the informed consent form.
* Female 18-75 years of age;
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
* Histologically or cytologically confirmed advanced cervical cancer, including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.

Exclusion Criteria:

* Patients were deemed unsuitable for participating in the study by the investigator for any reasons.

Where it's running

• Zhejiang Cancer Hospital
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Yongsheng Chu
• Email: chuys@zelgen.com
• Phone: +86-0512-57309965

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cervical screening and care options for women living with HIV who test positive for high-risk HPV

  This study tests different ways to screen and manage high-risk HPV in women with HIV to see what might work best for them.

  Recruiting University of California, San Diego · Nairobi · NCT07925307

• Hydrogel spacer to protect the rectum during cervical cancer radiotherapy

  This study tests whether placing an absorbable hydrogel spacer between the cervix/vagina and rectum before definitive radiotherapy can reduce rectal radiation exposure for women with cervical cancer.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07904182

• How cinema sessions during chemotherapy might help cervical cancer patients

  We’re testing if watching films during chemotherapy helps cervical cancer patients feel less anxious and improve quality of life.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT07902180

• One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy

  This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07895212

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• Gecacitinib for patients with myeloid neoplasms and myelofibrosis undergoing allogeneic stem cell transplant

  This study tests whether taking gecacitinib around the time of allogeneic stem cell transplantation is safe and helps engraftment in adults with myeloid neoplasms and myelofibrosis.

  Recruiting Phase 1/2 Ruijin Hospital · Shanghai · NCT07883382

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.